OraQuick Rapid HCV
Device
OraSure Technologies Inc.
Total Payments
$21,719
Transactions
11
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $20,049 | 8 | 0 |
| 2020 | $1,670 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $20,049 | 8 | 92.3% |
| Gift | $1,670 | 3 | 7.7% |
Payments by Type
Research
$20,049
8 transactions
General
$1,670
3 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Clinical Investigation to Evaluate the Performance of the OraQuick HCV Rapid Antibpody Test on Collected Sample Variations in Oral Fluid | OraSure Technologies Inc. | $17,049 | 0 |
| Investigation of the Performance of the OraQuick HCV Rapid Antibody Test Device with Raw Material Replacements | OraSure Technologies Inc. | $3,000 | 0 |
Top Doctors Receiving Payments for OraQuick Rapid HCV
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Cleveland, OH | $21,719 | 11 |
Ad
Manufacturing Companies
- OraSure Technologies Inc. $21,719
Product Information
- Type Device
- Total Payments $21,719
- Total Doctors 0
- Transactions 11
About OraQuick Rapid HCV
OraQuick Rapid HCV is a device associated with $21,719 in payments to 0 healthcare providers, recorded across 11 transactions in the CMS Open Payments database. The primary manufacturer is OraSure Technologies Inc..
Payment data is available from 2020 to 2021. In 2021, $20,049 was paid across 8 transactions to 0 doctors.
The most common payment nature for OraQuick Rapid HCV is "Unspecified" ($20,049, 92.3% of total).
OraQuick Rapid HCV is associated with 2 research studies, including "Clinical Investigation to Evaluate the Performance of the OraQuick HCV Rapid Antibpody Test on Collected Sample Variations in Oral Fluid" ($17,049).